Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02796300 · ClinicalTrials.gov registry record · NA
Study to Compare Palindrome vs. BioFlo DuraMax Dialysis Catheters
A NA study, sponsored by University of California, Los Angeles.
- Terminated
- Registry status
- NA
- Development phase
- 32
- Enrollment target
NCT02796300: Clinical Trial NA study, sponsored by University of California, Los Angeles.
NCT02796300 is a NA study that was terminated before completion, run by University of California, Los Angeles. The registered enrollment target is 32 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02796300, a NA study, was terminated before completion, sponsored by University of California, Los Angeles.
- TERMINATED
- Registry status
- NA
- Development phase
- 32 participants
- Enrollment target
Study Summary
Numerous catheter designs have been studied to increase efficacy and minimize complications of catheter hemodialysis. Major complications of catheters include thrombosis, central venous stenosis, infection, and dialysis inadequacy. Thrombosis must be avoided if possible because using too many catheters may exhaust all of the catheter insertion sites on the body, as well as increase the risk of infection. This prospective study compares the complications and general outcomes of patients who receive hemodialysis using the mainstream Palindrome catheter versus the newer BioFlo DuraMax catheter. This study will examine outcomes of patients who receive hemodialysis using either the Palindrome catheter or the BioFlo catheter. Patients will be observed and outcomes will be recorded for three to six months. Outcomes will be analyzed and compared to draw conclusions on which catheter produces less catheter thrombosis.
Primary Outcome
A comparison of the number of tPA used as an indicator of thrombosed catheter per month between two groups
Interventions
- DEVICE Bioflo Dialysis Catheter
- DEVICE Palindrome Dialysis Catheter
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2017-01-20 |
| Est. Completion | 2019-06-25 |
| Phase | NA |
Why NCT02796300 stopped before completion
NCT02796300 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Bioflo Dialysis Catheter is the first listed.
NCT02796300 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02796300 about?
NCT02796300 is a clinical study titled "Study to Compare Palindrome vs. BioFlo DuraMax Dialysis Catheters". Numerous catheter designs have been studied to increase efficacy and minimize complications of catheter hemodialysis. Major complications of catheters include thrombosis, central venous stenosis, infection, and dialysis inadequacy. Thrombosis must be avoided if possible because using too many cathet...
What is the current status of trial NCT02796300?
This trial is currently terminated. It is a NA study. The enrollment target is 32 participants. The study started on 2017-01-20. Estimated completion is 2019-06-25.
What interventions are being tested in trial NCT02796300?
The interventions under investigation include: Bioflo Dialysis Catheter (DEVICE), Palindrome Dialysis Catheter (DEVICE).
Who is sponsoring clinical trial NCT02796300?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02796300's enrollment target sits among peer trials
32 1578th of 2000 higher than 409 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI